Patients Fight for Access to BrainStorm’s ALS Drug After Expanded Access Data ‘Defy Logic’

Participants in trials of BrainStorm Cell Therapeutics’ NurOwn filed a Citizens’ Petition with the FDA earlier this month seeking a new review of the stem cell therapy that was rejected in 2022 based on real-world data and 90% survival in an expanded access program.